Weekly Recap: US FDA combination filing and China sovleplenib review

What happened

Hutchmed China and AstraZeneca filed a US application in September 2026 seeking review of ORPATHYS plus TAGRISSO. China’s drug regulator is reviewing Hutchmed applications for sovleplenib for primary ITP and warm antibody autoimmune hemolytic anemia, following positive pivotal trial results. Hutchmed also scheduled a Nov. 5 webcast on Phase III savolitinib data and regulatory outlook.

Confirmed

Global impact / market context

US review and China’s ongoing reviews are regulatory steps, not approval. If regulators eventually authorize these treatments, Hutchmed and AstraZeneca could gain routes to sell them, potentially adding revenue; delays or rejection would postpone or prevent that opportunity. The webcast may clarify savolitinib’s data and next steps.

Analyst inference

The article describes several drug programs at different stages: ORPATHYS plus TAGRISSO has entered US review, sovleplenib applications are under review in China, and savolitinib data will be discussed at a webcast. These developments concern future approval and sales potential, not confirmed commercial revenue.

Analyst inference

What to watch

1. Watch for US FDA decisions on the ORPATHYS plus TAGRISSO application; the filing confirms review has been sought, but the article gives no decision date or outcome. Analyst inference
2. Watch for updates from China’s regulator on sovleplenib for primary ITP and warm antibody autoimmune hemolytic anemia, including whether review leads to approval. Analyst inference
3. The Nov. 5 webcast is scheduled to discuss Phase III savolitinib data from China’s SANOVO and global SAFFRON studies, plus the regulatory outlook. Confirmed

Evidence

• Original source link unavailable